XSTO
NEEMS B
Market cap7mUSD
Aug 12, Last price
3.10SEK
Name
Scandinavian ChemoTech AB
Chart & performance
P/E
—
P/S
6.01
EPS
—
Div yield, %
—
Shrs. gr., 5y
37.30%
Rev. gr., 5y
147.98%
Revenues
12m
+87.10%
Net income
-8m
L-41.27%
CFO
-4m
L-71.51%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.
Key people
Stefan Frick
Chief Executive Officer, Director
Johan Marnfeldt
Director of Products & Quality
Suhail Mufti
Medical Director · since 2022
Ann Ohlsson
Finance Manager · since 2020
Chairman of the Board · since 2019
Goran Hellers
Director
Director · since 2019
Headquarters & legal address
C/O Medicon Village
Scheeletorget 1
Lund, M 223 63
SE
Scheeletorget 1
Lund, M 223 63
SE
Previous name
Blidöprojektet AB
Previous name
Grundbulten 7090 AB
Previous name
Scandinavian ChemoTech AB (publ)
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||